A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee

Clinical Therapeutics

Volumn 28, Issue 3, 2006, Pages 352-364

  Kivitz, Alan ^a   Ma, Carl ^b   Ahdieh, Harry ^c   Galer, Bradley S ^c,d  

^a Altoona Center for Clinical Research   (United States)

^b PharmStats Ltd   (United States)

^c ENDO PHARMACEUTICALS INC   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

analgesics; opioid; osteoarthritis; oxymorphone; pain

Indexed keywords

ANALGESIC AGENT; OPIATE; OXYMORPHONE; PLACEBO;

ADULT; ANALGESIC ACTIVITY; APPETITE DISORDER; ARTHRALGIA; ARTICLE; CENTRAL NERVOUS SYSTEM DEPRESSION; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; EUPHORIA; FATIGUE; FEMALE; FINGER JOINT; HIP OSTEOARTHRITIS; HUMAN; HYPERHIDROSIS; INDEX FINGER; JOINT STIFFNESS; KNEE OSTEOARTHRITIS; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; MULTICENTER STUDY; NAUSEA; PAIN ASSESSMENT; PANCREATITIS; PHASE 3 CLINICAL TRIAL; PHYSICAL ACTIVITY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REGRESSION ANALYSIS; SHORT FORM 36; SIDE EFFECT; SOMNOLENCE; URINE RETENTION; VISUAL ANALOG SCALE; VITAL SIGN; VOMITING; XEROSTOMIA;

ANALGESICS, OPIOID; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS, HIP; OSTEOARTHRITIS, KNEE; OXYMORPHONE; PAIN MEASUREMENT; SLEEP; TREATMENT OUTCOME;

EID: 33646872448     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.03.008     Document Type: Article

References (48)

1. Resnik D.B., Rehm M., and Minard R.B. The undertreatment of pain: Scientific, clinical, cultural, and philosophical factors. Med Health Care Philos 4 (2001) 277-288
2. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee. Arthritis Rheum 43 (2000) 1905-1915
3. American Pain Society. Guideline for the Management of Pain in Osteoarthritis, Rheumatoid Arthritis and Juvenile Chronic Arthritis. 2nd ed. (2002), American Pain Society, Glenview, III
4. Peloso P.M., Bellamy N., Bensen W., et al. Double blind randomized placebo control trial of controlled release codeine in the treatment of osteoarthritis of the hip or knee. J Rheumatol 27 (2000) 764-771
5. Caldwell J.R., Rapoport R.J., Davis J.C., et al. Efficacy and safety of a oncedaily morphine formulation in chronic, moderate-to-severe osteoarthritis pain: Results from a randomized, placebo-controlled, double-blind trial and an open-label extension trial. J Pain Symptom Manage 23 (2002) 278-291
6. Markenson J.A., Croft J., Zhang P.G., and Richards P. Treatment of persistent pain associated with osteoarthritis with controlled-release oxycodone tablets in a randomized controlled clinical trial. Clin J Pain 21 (2005) 524-535
7. Adler L., McDonald C., O'Brien C., and Wilson M. A comparison of oncedaily tramadol with normal release tramadol in the treatment of pain in osteoarthritis. J Rheumatol 29 (2002) 2196-2199
8. Bellamy N., Carette S., Ford P.M., et al. Osteoarthritis antirheumatic drug trials. III. Setting the delta for clinical trials-results of a consensus development (Delphi) exercise. J Rheumatol 19 (1992) 451-457
9. Ripamonti C., and Dickerson E.D. Strategies for the treatment of cancer pain in the new millennium. Drugs 61 (2001) 955-977
10. Uhl G.R., Sora I., and Wang Z. The mu opiate receptor as a candidate gene for pain: Polymorphisms, variations in expression, nociception, and opiate responses. Proc Natl Acad Sci USA 96 (1999) 7752-7755
11. Cherny N., Ripamonti C., Pereira J., et al. Strategies to manage the adverse effects of oral morphine: An evidencebased report. J Clin Oncol 19 (2001) 2542-2554
12. Indelicato R.A., and Portenoy R.K. Opioid rotation in the management of refractory cancer pain. J Clin Oncol 20 (2002) 348-352
13. Quang-Cantagrel N.D., Wallace M.S., and Magnuson S.K. Opioid substitution to improve the effectiveness of chronic noncancer pain control: A chart review. Anesth Analg 90 (2000) 933-937
14. American Pain Society 2002 Abstract Database. Available at:. Adams D., Royal M., Jenson M.G., et al. Retrospective assessment of frequency of dosing of sustained re lease opiate preparations. Accessed. American Pain Society 21st Scientific Meeting. March 14-17, 2002 (December 6, 2005). http://www.ampainsoc.org/db2/abstract/view?poster_id=1088
15. Metzger T.G., Paterlini M.G., Ferguson D.M., and Portoghese P.S. Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via sitedirected mutagenesis of opioid receptors: Exploring the"address" recognition locus. J Med Chem 44 (2001) 857-862
16. Eddy N.B., and Lee L.E.J. The analgesic equivalence to morphine and relative side action liability of oxymorphone (4-hydroxydihydromorphinone). J Pharmacol Exp Ther 125 (1959) 116-121
17. Adams M.P., and Ahdieh H. Pharmacokinetics and dose-proportionality of oxymorphone extended release and its metabolites: Results of a randomized crossover study. Pharmacotherapy 24 (2004) 468-476
18. Ahdieh H., Ma T., Babul N., and Lee D. Efficacy of oxymorphone extended release in postsurgical pain: A ran domized clinical trial in knee arthroplasty. J Clin Pharmacol 44 (2004) 767-776
19. Gabrail N.Y., Dvergsten C., and Ahdieh H. Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: A randomizedcontrolled study. Curr Med Res Opin 20 (2004) 911-918
20. McIlwain H., and Ahdieh H. Safety, tolerability, and effectiveness of oxymorphone extended release for moderate to severe osteoarthritis pain: A oneyear study. Am J Ther 12 (2005) 106-112
21. Hale M.E., Dvergsten C., and Gimbel J. Efficacy and safety of oxymorphone extended release in chronic low back pain: Results of a randomized, double-blind, placebo- and activecontrolled phase III study. J Pain 6 (2005) 21-28
22. Matsumoto A.K., Babul N., and Ahdieh H. Oxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: Results of a randomized, double-blind, placebo- and activecontrolled phase III trial. Pain Med 6 (2005) 357-366
23. Kellgren J.H., and Lawrence J.S. Osteoarthritis and disk degeneration in an urban population. Ann Rheum Dis 17 (1958) 388-396
24. Shih C.J., Doufas A.G., Chang H.C., and Lin C.M. Recurrent seizure activity after epidural morphine in a post-partum woman. Can J Anaesth 52 (2005) 727-729
25. Borgeat A., Biollaz J., Depierraz B., and Neff R. Grand mal seizure after extradural morphine analgesia. Br J Anaesth 60 (1988) 733-735
26. Orlando, Fla. Matsumoto A., Babul N., Ahdieh H., and Ma T. A placebo-and active-controlled trial of oxymorphone extended re lease for moderate to severe pain in osteoarthritis of the knee and hip. Presented at the American College of Rheumatology ACR/ARHP 67th Annual Scientific Meeting (October 23-28, 2003)
27. December. Guideline for the Clinical Evaluation of Analgesic Drugs (1992), US Dept of Health and Human Ser vices, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Rockville, Md
28. Bellamy N., Buchanan W.W., Goldsmith C.H., et al. Validation study of WOMAC: A health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy inpatients with osteoarthritis of the hip or knee. J Rheumatol 15 (1988) 1833-1840
29. Ware Jr. J.E., and Sherbourne C.D. The MOS 36-item short-form health survey (SF-36). I. Conceptual frame work and item selection. Med Care 30 (1992) 473-483
30. Babul N., Noveck R., Chipman H., et al. Efficacy and safety of extendedrelease, once-daily tramadol in chron ic pain: A randomized 12-week clinical trial in osteoarthritis of the knee. J Pain Symptom Manage 28 (2004) 59-71
31. International Conference on Harmonisation, Medical Dictionary for Regulatory Activities (MedDRA) (September 16, 2004). http://www.meddramsso.com/NewWeb2003/index.htm
32. Bellamy N., Carette S., Ford P.M., et al. Osteoarthritis antirheumatic drug trials. II. Tables for calculating sam ple size for clinical trials. J Rheumatol 19 (1992) 444-450
33. Tukey J.W., Ciminera J.L., and Heyse J.F. Testing the statistical certainty of a response to increasing doses of a drug. Biometrics 41 (1985) 295-301
34. Fleiss J., Levin B., and Paik M. Statistical Methods for Rates and Populations. 3rd ed. (2003), John Wiley & Sons, Inc, Hoboken, NJ
35. Caldwell J.R., Hale M.E., Boyd R.E., et al. Treatment of osteoarthritis pain with controlled release oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal antiinflammatory drugs: A double blind, randomized, multicenter, placebo controlled trial. J Rheumatol 26 (1999) 862-869
36. (Suppl). Bope E.T., Douglass A.B., Gibovsky A., et al. Pain management by the family physician: The family practice pain education project. J Am Board Fam Pract 17 (2004) S1-S12
37. Roth S.H., Fleischmann R.M., Burch F.X., et al. Around-the-clock, controlled release oxycodone therapy for osteoarthritis-related pain: Placebocontrolled trial and long-term evaluation. Arch Intern Med 160 (2000) 853-860
38. Marcus D.A., and Glick R.M. Sustainedrelease oxycodone dosing survey of chronic pain patients. Clin J Pain 20 (2004) 363-366
39. Ross F.B., and Smith M.T. The intrinsic antinociceptive effects of oxycodone appear to be kappa-opioid receptor mediated. Pain 73 (1997) 151-157
40. Sawchuk R.J., and Elmquist W.F. Microdialysis in the study of drug transporters in the CNS. Adv Drug Deliv Rev 45 (2000) 295-307
41. Klepstad P., Dale O., Skorpen F., et al. Genetic variability and clinical efficacy of morphine. Acta Anaesthesiol Scand 49 (2005) 902-908
42. Kharasch E.D., Hoffer C., Whittington D., and Sheffels P. Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine. Clin Pharmacol Ther 74 (2003) 543-554
43. Available at:. Flockhart D.A. Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine. Accessed (December 6, 2005). http://www.medicine.iupui.edu/Fockhart/table.htm
44. Heiskanen T., Kalso E., and Olkkola K.T. Effects of blocking CYP2D6 on the pharmacokinetics and pharmacody namics of oxycodone. Clin Pharmacol Ther. 64 (1998) 603-611
45. Tegeder I., Lotsch J., and Geisslinger G. Pharmacokinetics of opioids in liver disease. Clin Pharmacokinet 37 (1999) 17-40
46. Ravenscroft P., and Schneider J. Bedside perspectives on the use of opioids: Transferring results of clinical research into practice. Clin Exp Pharmacol Physiol 27 (2000) 529-532
47. Lalovic B., Phillips B., Risler L.L., et al. Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos 32 (2004) 447-454
48. Adams M., Pieniaszek Jr. H.J., Gammaitoni A.R., and Ahdieh H. Oxymorphone extended release does not affect CYP2C9 or CYP3A4 metabolic pathways. J Clin Pharmacol 45 (2005) 337-345